Vaccitech Newsroom
News & updates
Vaccitech to Present at Solebury Trout Virtual Investor Conference
Oxford, UK – 30th March 2020 Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company’s progress...
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Oxford, UK – Vaccitech Limited and the University of Oxford today announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in patients with metastatic castration resistant prostate cancer (mCRPC)....
Vacancy: Clinical Programme Lead
To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs in accordance with quality requirements,...
Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
Oxford, UK – Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat cancer and chronic infectious diseases, announces top line Phase 2 data and plans for its recombinant Modified Vaccinia Ankara (MVA) Universal Influenza A...
New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia
Vaccitech’s partner, the University of Oxford’s Jenner Institute, in collaboration with The King Abdullah International Medical Research Centre (KAIMRC), announced that it has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against...
Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
Oxford, UK – 18 December 2019: Vaccitech Ltd announced today that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical partnership with Cancer Research UK to develop VOLT’s...
Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studies
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020 Oxford, United Kingdom – 25th November 2019: Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing...
Vaccitech to present clinical development of Universal Influenza A Vaccine (VTP-100) in pandemic and seasonal indications at World Vaccine Congress Europe
Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases, will present an update on the development of its Universal influenza A vaccine MVA-NP+M1 (VTP-100) at the World Vaccine Congress in...
Vaccitech Appoints Bill Enright as New Chief Executive Officer
Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who...
Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent Cancer and Infectious Diseases, announces today that it has appointed Mariem Charafeddine as Chief Medical Officer. Mariem brings over 15 years’...